Report cover image

Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD): Competitive Landscape

Publisher GlobalData
Published Feb 28, 2025
Length 70 Pages
SKU # GBDT20050935

Description

Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD): Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics.
  • GlobalData epidemiologists estimate that there were 1.19 million diagnosed prevalent cases of Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PKD & ADPKD) infection in 2024, which is expected to increase slightly to 1,23 million diagnosed prevalent cases by 2029.
  • Currently, there is only one approved innovator therapy available on the market specifically for treating ADPKD.
  • The PKD pipeline holds 43 molecules across all stages of R&D. However, none of the molecules are at the pre-registration stage for PKD.
  • Over the past 10 years, 89 clinical trials have been conducted in PKD.
  • During the past decade, acquisitions were North America’s most common deal type.
Scope

GlobalData’s Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

70 Pages
  • Key Findings
    • Disease Etiology
    • Epidemiology Overview - Diagnosed Prevalent Cases of ADPKD in 2024 and 2029
    • Management Algorithm for PKD
    • Dosing of Tolvaptan for ADPKD
    • Marketed Drugs - Leading Marketed Drugs in PKD
    • Marketed Drug Profile - Otsuka Pharmaceutical’s Jinarc/Jynarque/Samsca
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Jinarc/Jynarque/Samsca
    • Pipeline Drugs Overview - Clinical-Stage Pipeline Drugs in PKD
    • Pipeline Drugs Overview - Preclinical Pipeline Drugs in PKD
    • Pipeline Drugs Overview - Discovery Pipeline Drugs in PKD
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in Genitourinary System and PKD
    • Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in PKD
    • Clinical Trials in PKD - Historical Overview
    • Clinical Trials in PKD - Overview by Phase
    • Clinical Trials in PKD - Overview by Status
    • Clinical Trials in PKD - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in PKD - Trials with a Virtual Component
    • Clinical Trials in PKD - Geographic Overview
    • Clinical Trials in PKD - Single-Country and Multinational Trials by Region
    • Clinical Trials in PKD - Top Sponsors with Breakdown by Phase
    • Clinical Trials in PKD - Top Sponsors with Breakdown by Status
    • Clinical Trials in PKD - Overview by Endpoint Status
    • Clinical Trials in PKD - Overview by Race and Ethnicity
    • Clinical Trials in PKD - Enrollment Data
    • Clinical Trials in PKD - Overview of Sites by Geography
    • Clinical Trials in PKD - Top 20 Countries for Trial Sites
    • Clinical Trials in PKD - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for PKD
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in PKD by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in PKD
    • Commercial Assessment - Key Market Players in PKD
    • Future Market Catalysts - Upcoming Market Catalysts in PKD
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us